


What is claimed is:

1. A method of treating migraine, epilepsy, or bipolar disorder in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I)



(I),

or a pharmaceutically acceptable prodrug thereof, wherein


A is cycloalkyl or bicycloalkyl;

R<sub>A</sub>, R<sub>B</sub>, and R<sub>C</sub> are independently hydrogen or alkyl;

R<sub>1</sub> is OR<sub>2</sub> or NR<sub>3</sub>R<sub>4</sub>;

R<sub>2</sub> is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, or heterocyclealkyl;

R<sub>3</sub> and R<sub>4</sub> are independently hydrogen, alkenyl, alkyl, alkynyl, alkoxycarbonylalkyl, aryl, arylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, (NR<sub>5</sub>R<sub>6</sub>)alkyl, (NR<sub>5</sub>R<sub>6</sub>)carbonylalkyl, or



; or

R<sub>3</sub> and R<sub>4</sub> taken together with the nitrogen atom to which they are attached form a heterocycle wherein the heterocycle is azepanyl, azetidiny, aziridiny, morpholinyl, piperaziny, piperidiny, pyrrolidiny, or thiomorpholinyl;

R<sub>5</sub> and R<sub>6</sub> are independently hydrogen, alkenyl, alkyl, alkynyl, alkoxycarbonylalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, or hydroxyalkyl;

R<sub>7</sub> is alkoxy, alkyl, hydroxy, or -NR<sub>5</sub>R<sub>6</sub>;

R<sub>8</sub> is alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkylthioalkyl, alkynyl, aryl, arylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, mercaptoalkyl, (NR<sub>5</sub>R<sub>6</sub>)alkyl, (NR<sub>5</sub>R<sub>6</sub>)carbonylalkyl, or -(CH<sub>2</sub>)<sub>n</sub>NHC(=NH)NH<sub>2</sub>; and

n is an integer from 1 to 6.

2. The method according to claim 1 wherein

A is cycloalkyl; and

R<sub>1</sub> is OR<sub>2</sub>.

3. The method according to claim 1 wherein

A is cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with 1, 2, 3, or 4 alkyl groups;

R<sub>1</sub> is OR<sub>2</sub>; and

R<sub>2</sub> is hydrogen.

4. The method according to claim 3 wherein the compound of formula (I) is

spiro[2.5]octane-1-carboxylic acid;

(1S)-spiro[2.5]octane-1-carboxylic acid;

(1R)-spiro[2.5]octane-1-carboxylic acid;

2-methylspiro[2.5]octane-1-carboxylic acid;

5,7-dimethylspiro[2.5]octane-1-carboxylic acid;

6-tert-butylspiro[2.5]octane-1-carboxylic acid;

(4S,7R)-4-isopropyl-7-methylspiro[2.5]octane-1-carboxylic acid; or

5,5,7,7-tetramethylspiro[2.5]octane-1-carboxylic acid.

5. The method according to claim 1 wherein

A is cycloalkyl wherein the cycloalkyl is bicyclo[3.1.1]hept-2-yl, bicyclo[2.2.1]hept-2-yl, cycloheptyl, cyclopentyl, or cyclooctyl, wherein the cycloalkyl is optionally substituted with 1, or 2 alkyl groups;

R<sub>1</sub> is OR<sub>2</sub>; and

R<sub>2</sub> is hydrogen.

6. The method according to claim 5 wherein the compound of formula (I) is

spiro[2.4]heptane-1-carboxylic acid;

(1R,5S)-6,6-dimethylspiro[bicyclo[3.1.1]heptane-2,1'-cyclopropane]-2'-carboxylic acid;

2-methylspiro[2.4]heptane-1-carboxylic acid;

3,3-dimethylspiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxylic acid;

spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxylic acid;

spiro[2.6]nonane-1-carboxylic acid; or  
spiro[2.7]decane-1-carboxylic acid.

7. The method according to claim 1 wherein  
A is bicycloalkyl; and  
R<sub>1</sub> is OR<sub>2</sub>.
8. The method according to claim 1 wherein  
A is bicycloalkyl wherein the bicycloalkyl is bicyclo[3.2.0]hept-6-yl or decahydro-2-naphthalenyl wherein the bicycloalkyl is optionally substituted with 1, or 2 alkyl groups;  
R<sub>1</sub> is OR<sub>2</sub>; and  
R<sub>2</sub> is hydrogen.
9. The method according to claim 8 wherein the compound of formula (I) is  
4-methylspiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxylic acid;  
octahydro-1'H-spiro[cyclopropane-1,2'-naphthalene]-2-carboxylic acid; or  
spiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxylic acid.
10. The method according to claim 1 wherein  
A is cycloalkyl; and  
R<sub>1</sub> is NR<sub>3</sub>R<sub>4</sub>.
11. The method according to claim 1 wherein  
A is cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with 1, 2, 3, or 4 alkyl groups;  
R<sub>1</sub> is NR<sub>3</sub>R<sub>4</sub>;  
R<sub>4</sub> is hydrogen or (NR<sub>5</sub>R<sub>6</sub>)carbonylalkyl; and  
R<sub>3</sub>, R<sub>5</sub>, and R<sub>6</sub> are hydrogen.
12. The method according to claim 11 wherein the compound of formula (I) is  
spiro[2.5]octane-1-carboxamide;  
N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide;  
(1S)-N-[(1S)-2-amino-1-methyl-2-oxoethyl]spiro[2.5]octane-1-carboxamide;

(1R)-N-[(1S)-2-amino-1-methyl-2-oxoethyl]spiro[2.5]octane-1-carboxamide;  
 (1S)-spiro[2.5]octane-1-carboxamide;  
 (1R)-spiro[2.5]octane-1-carboxamide;  
 2-methylspiro[2.5]octane-1-carboxamide;  
 N-(2-amino-2-oxoethyl)-2-methylspiro[2.5]octane-1-carboxamide;  
 5,7-dimethylspiro[2.5]octane-1-carboxamide;  
 N-(2-amino-2-oxoethyl)-5,7-dimethylspiro[2.5]octane-1-carboxamide;  
 6-tert-butylspiro[2.5]octane-1-carboxamide;  
 N-(2-amino-2-oxoethyl)-6-tert-butylspiro[2.5]octane-1-carboxamide;  
 (4S,7R)-4-isopropyl-7-methylspiro[2.5]octane-1-carboxamide;  
 (4S,7R)-N-(2-amino-2-oxoethyl)-4-isopropyl-7-methylspiro[2.5]octane-1-carboxamide;  
 N-(3-amino-3-oxopropyl)spiro[2.5]octane-1-carboxamide;  
 5,5,7,7-tetramethylspiro[2.5]octane-1-carboxamide; or  
 N-(2-amino-2-oxoethyl)-5,5,7,7-tetramethylspiro[2.5]octane-1-carboxamide.

13. The method according to claim 11 wherein the compound of formula (I) is (1S)-N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide.

14. The method according to claim 11 wherein the compound of formula (I) is (1R)-N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide.

15. The method according to claim 1 wherein

A is cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with 1, 2, 3, or 4 alkyl groups;

R<sub>1</sub> is NR<sub>3</sub>R<sub>4</sub>;

R<sub>4</sub> is carboxyalkyl or hydroxyalkyl; and

R<sub>3</sub> is hydrogen.

16. The method according to claim 15 wherein the compound of formula (I) is

[(spiro[2.5]oct-1-ylcarbonyl)amino]acetic acid;

{[(1S)-spiro[2.5]oct-1-ylcarbonyl]amino}acetic acid;

{[(1R)-spiro[2.5]oct-1-ylcarbonyl]amino}acetic acid;

(1R)-N-[(2R)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide;  
 (1R)-N-[(2S)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide;  
 (1S)-N-[(2R)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide; or  
 (1S)-N-[(2S)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide.

17. The method according to claim 1 wherein

A is cycloalkyl wherein the cycloalkyl is bicyclo[3.1.1]hept-2-yl, bicyclo[2.2.1]hept-2-yl, cycloheptyl, cyclopentyl, or cyclooctyl, wherein the cycloalkyl is optionally substituted with 1 or 2 alkyl groups;

R<sub>1</sub> is NR<sub>3</sub>R<sub>4</sub>;

R<sub>4</sub> is hydrogen or (NR<sub>5</sub>R<sub>6</sub>)carbonylalkyl; and

R<sub>3</sub>, R<sub>5</sub>, and R<sub>6</sub> are hydrogen.

18. The method according to claim 17 wherein the compound of formula (I) is

spiro[2.4]heptane-1-carboxamide;

N-(2-amino-2-oxoethyl)spiro[2.4]heptane-1-carboxamide;

(1R,5S)-6,6-dimethylspiro[bicyclo[3.1.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

(1R,5S)-N-(2-amino-2-oxoethyl)-6,6-dimethylspiro[bicyclo[3.1.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

2-methylspiro[2.4]heptane-1-carboxamide;

N-(2-amino-2-oxoethyl)-2-methylspiro[2.4]heptane-1-carboxamide;

3,3-dimethylspiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

N-(2-amino-2-oxoethyl)-3,3-dimethylspiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

N-(2-amino-2-oxoethyl)spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxamide;

spiro[2.6]nonane-1-carboxamide;

N-(2-amino-2-oxoethyl)spiro[2.6]nonane-1-carboxamide;

spiro[2.7]decane-1-carboxamide; or

N-(2-amino-2-oxoethyl)spiro[2.7]decane-1-carboxamide.

19. The method according to claim 1 wherein

A is bicycloalkyl; and

R<sub>1</sub> is NR<sub>3</sub>R<sub>4</sub>.

20. The method according to claim 1 wherein

A is bicycloalkyl wherein the bicycloalkyl is bicyclo[3.2.0]hept-6-yl or decahydro-2-naphthalenyl wherein the bicycloalkyl is optionally substituted with 1 or 2 alkyl groups;

R<sub>1</sub> is NR<sub>3</sub>R<sub>4</sub>;

R<sub>4</sub> is hydrogen or (NR<sub>5</sub>R<sub>6</sub>)carbonylalkyl; and

R<sub>3</sub>, R<sub>5</sub>, and R<sub>6</sub> are hydrogen.

21. The method according to claim 20 wherein the compound of formula (I) is

4-methylspiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxamide;

N-(2-amino-2-oxoethyl)-4-methylspiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxamide;

octahydro-1'H-spiro[cyclopropane-1,2'-naphthalene]-2-carboxamide;

N-(2-amino-2-oxoethyl)octahydro-1'H-spiro[cyclopropane-1,2'-naphthalene]-2-carboxamide;

spiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxamide; or

N-(2-amino-2-oxoethyl)spiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxamide.


22. A method of treating pain, a movement disorder, or a psychiatric disorder in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).

23. The method according to claim 22 wherein the compound of formula (I) is (1R)-N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide.

24. A method of providing neuroprotection in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).

25. The method according to claim 24 wherein the compound of formula (I) is (1R)-N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide.

26. A compound of formula (II)




or a pharmaceutically acceptable prodrug thereof, wherein

A is cycloalkyl or bicycloalkyl wherein the cycloalkyl and bicycloalkyl are optionally substituted with 1, 2, 3, or 4 alkyl groups;

R<sub>A</sub>, R<sub>B</sub>, and R<sub>C</sub> are independently hydrogen or alkyl;

R<sub>3</sub> is alkenyl, alkynyl, alkoxycarbonylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, (NR<sub>5</sub>R<sub>6</sub>)alkyl, or (NR<sub>5</sub>R<sub>6</sub>)carbonylalkyl;

R<sub>4</sub> is hydrogen, alkenyl, alkyl, alkynyl, alkoxycarbonylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, (NR<sub>5</sub>R<sub>6</sub>)alkyl, or (NR<sub>5</sub>R<sub>6</sub>)carbonylalkyl, or



R<sub>3</sub> and R<sub>4</sub> taken together with the nitrogen atom to which they are attached form a heterocycle wherein the heterocycle is azepanyl, azetidiny, aziridiny, morpholiny, piperaziny, piperidiny, pyrrolidiny, or thiomorpholiny;

R<sub>5</sub> and R<sub>6</sub> are independently hydrogen, alkenyl, alkyl, alkynyl, alkoxycarbonylalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, or heterocyclealkyl;

R<sub>7</sub> is alkoxy, alkyl, hydroxy, or -NR<sub>5</sub>R<sub>6</sub>;

R<sub>8</sub> is alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkylthioalkyl, alkynyl, aryl, arylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, mercaptoalkyl, (NR<sub>5</sub>R<sub>6</sub>)alkyl, (NR<sub>5</sub>R<sub>6</sub>)carbonylalkyl, or -(CH<sub>2</sub>)<sub>n</sub>NHC(=NH)NH<sub>2</sub>; and

n is an integer from 1 to 6.

27. The compound according to claim 26 wherein A is cycloalkyl optionally substituted with 1, 2, 3, or 4 alkyl groups.
28. The compound according to claim 26 wherein  
A is cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with 1, 2, 3, or 4 alkyl groups;  
R<sub>3</sub> is (NR<sub>5</sub>R<sub>6</sub>)carbonylalkyl; and  
R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> are hydrogen.
29. The compound according to claim 28 wherein the compound of formula (II) is  
N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide;  
(1S)-N-[(1S)-2-amino-1-methyl-2-oxoethyl]spiro[2.5]octane-1-carboxamide;  
(1R)-N-[(1S)-2-amino-1-methyl-2-oxoethyl]spiro[2.5]octane-1-carboxamide;  
N-(2-amino-2-oxoethyl)-2-methylspiro[2.5]octane-1-carboxamide;  
N-(2-amino-2-oxoethyl)-5,7-dimethylspiro[2.5]octane-1-carboxamide;  
N-(2-amino-2-oxoethyl)-6-tert-butylspiro[2.5]octane-1-carboxamide;  
(4S,7R)-N-(2-amino-2-oxoethyl)-4-isopropyl-7-methylspiro[2.5]octane-1-carboxamide;  
N-(3-amino-3-oxopropyl)spiro[2.5]octane-1-carboxamide; or  
N-(2-amino-2-oxoethyl)-5,5,7,7-tetramethylspiro[2.5]octane-1-carboxamide.
30. The compound according to claim 28 wherein the compound of formula (II) is (1S)-N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide.
31. The compound according to claim 28 wherein the compound of formula (II) is (1R)-N-(2-amino-2-oxoethyl)spiro[2.5]octane-1-carboxamide.
32. The compound according to claim 26 wherein  
A is cycloalkyl wherein the cycloalkyl is cyclohexyl optionally substituted with 1, 2, 3, or 4 alkyl groups;  
R<sub>3</sub> is carboxyalkyl or hydroxyalkyl; and  
R<sub>4</sub> is hydrogen.



33. The compound according to claim 32 wherein the compound of formula (II) is  
 [(spiro[2.5]oct-1-ylcarbonyl)amino]acetic acid;  
 {[ (1S)-spiro[2.5]oct-1-ylcarbonyl]amino}acetic acid;  
 {[ (1R)-spiro[2.5]oct-1-ylcarbonyl]amino}acetic acid;  
 (1R)-N-[(2R)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide;  
 (1S)-N-[(2R)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide;  
 (1R)-N-[(2S)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide; or  
 (1S)-N-[(2S)-2-hydroxypropyl]spiro[2.5]octane-1-carboxamide.
34. The compound according to claim 26 wherein  
 A is cycloalkyl wherein the cycloalkyl is bicyclo[3.1.1]hept-2-yl, bicyclo[2.2.1]hept-2-yl, cycloheptyl, cyclopentyl, or cyclooctyl, wherein the cycloalkyl is optionally substituted with 1 or 2 alkyl groups;  
 R<sub>3</sub> is (NR<sub>5</sub>R<sub>6</sub>)carbonylalkyl; and  
 R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> are hydrogen.
35. The compound according to claim 34 wherein the compound of formula (II) is  
 N-(2-amino-2-oxoethyl)spiro[2.4]heptane-1-carboxamide;  
 (1R,5S)-N-(2-amino-2-oxoethyl)-6,6-dimethylspiro[bicyclo[3.1.1]heptane-2,1'-cyclopropane]-2'-carboxamide;  
 N-(2-amino-2-oxoethyl)-2-methylspiro[2.4]heptane-1-carboxamide;  
 N-(2-amino-2-oxoethyl)-3,3-dimethylspiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxamide;  
 N-(2-amino-2-oxoethyl)spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-2'-carboxamide;  
 N-(2-amino-2-oxoethyl)spiro[2.6]nonane-1-carboxamide; or  
 N-(2-amino-2-oxoethyl)spiro[2.7]decane-1-carboxamide.
36. The compound according to claim 26 wherein A is bicycloalkyl optionally substituted with 1, 2, 3, or 4 alkyl groups.
37. The compound according to claim 26 wherein

A is bicycloalkyl wherein the bicycloalkyl is bicyclo[3.2.0]hept-6-yl or decahydro-2-naphthalenyl, wherein the bicycloalkyl is optionally substituted with 1 or 2 alkyl groups;

R<sub>3</sub> is (NR<sub>5</sub>R<sub>6</sub>)carbonylalkyl; and

R<sub>4</sub>, R<sub>5</sub>, and R<sub>6</sub> are hydrogen.

38. The compound according to claim 37 wherein the compound of formula (II) is

N-(2-amino-2-oxoethyl)-4-methylspiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxamide;

N-(2-amino-2-oxoethyl)octahydro-1'H-spiro[cyclopropane-1,2'-naphthalene]-2-carboxamide; or

N-(2-amino-2-oxoethyl)spiro[bicyclo[3.2.0]heptane-6,1'-cyclopropane]-2'-carboxamide.

39. A method of treating neuropathic and inflammatory pain in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).